RxDoctor Payments DataLook up a doctor →

Charles Withers, MD

Rheumatology · Charlotte, NCNPI 1598928202

Payments from drug & device makers

$148,649in general payments, 2019–2025

Across 768 payments — averaging $193.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$87K
  • Mallinckrodt Enterprises LLC$13K
  • Dr.reddy's Laboratories,inc.$13K
  • Mallinckrodt Hospital Products Inc.$10K
  • Amgen$8K
  • AstraZeneca$4K
  • plus $12K from 39 others

What the payments were for

  • Consulting fees$3,7803%
  • Speaking & faculty fees$103,95077%
  • Grants$2400%
  • Travel & lodging$12,3989%
  • Food & beverage$15,36511%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$148,649 in reported general payments places this provider in the 80th percentile of 210 rheumatology providers in North Carolina.

See all rheumatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$949,900
Medicare patients
182
Services billed
57,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab24$179,694
RinvoqUpadacitinib27$172,573
ForteoTeriparatide40$166,521
Cosentyx Sensoready (2 Pens)Secukinumab14$123,874
Enbrel MiniEtanercept16$117,367
Actemra ActpenTocilizumab14$98,724
KevzaraSarilumab21$85,253
BenlystaBelimumab15$69,947
Orencia ClickjectAbatacept12$66,976
Cimzia (2 Pack)Certolizumab Pegol12$65,672
ActemraTocilizumab15$49,971
Hydroxychloroquine Sulfate109$3,671
Celecoxib95$3,638
MethotrexateMethotrexate Sodium144$2,474
Duloxetine Hcl76$1,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,562$172,57327 claims
Lilly USA, LLCForteo$87,314$166,52140 claims
SanofiKevzara$185$85,25321 claims
GSKBenlysta$521$69,94715 claims
UCB, Inc.Cimzia (2 Pack)$1,323$65,67212 claims
Scilex Pharmaceuticals Inc.Colchicine$18$90312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 210 rheumatology providers in North Carolina.

Other rheumatology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →